Author(s):
Zyad Hussein J. AL-Qaisi, Alaa Hussein J. AL-Qaisi, Wessal M. Khamis, Zaman Ahmed Hussein, Iman Rajab Mohammed
Email(s):
wessalmetaab@yahoo.com , wessalmetaab@uomustansiriyah.edu.iq , zyadalqaisi@uomustansiriyah.edu.iq
DOI:
10.52711/0974-360X.2023.00071 
Address:
Zyad Hussein J. AL-Qaisi1, Alaa Hussein J. AL-Qaisi2, Wessal M. Khamis3*, Zaman Ahmed Hussein4, Iman Rajab Mohammed5
1Department of Chemistry, College of Science, Mustansiriyah University, Baghdad, Iraq.
2Department of chemistry, College of Science, AL-Nahrain University, Baghdad, Iraq.
*Corresponding Author
Published In:
Volume - 16,
Issue - 1,
Year - 2023
ABSTRACT:
For four decades, hepatitis often strikes hemodialysis (HD) patients. The seroprevalence of hepatitis infection in HD ranges from country to country. The study design of two parts, the first partisan estimate of the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) in Baghdad teaching hospital/departmentof HD, and the second part is an association between HBV, and HCV transmission and other suspected risk factors dental office and tattooing. A one hundred patients who underwent serum anti-HBC and anti-HCV examination at Baghdad teaching hospital/department of dialysis were enrolled in the study. The chemiluminescence assay has been used to test HBV and HCV antibodies, and an automated kinetic method was used for liver function tests. HCVAb was detected in thirty-five (35%) dialysis patients, and the total HBcAb and infection HBsAg were detected in five (5%) and zero (0%) respectively. No Co-infection was observed. Seroprevalence results related to transfusion requirement was 4 (7.4%) for total HBcAb, zero (0%) for HBsAg, and 32 (59.3%) for HCVAb. There was no significant difference between blood transfusion and non-transfusion in risk prevalence of total HBcAb and HBsAg, but the risk of HCV infection was significantly higher in the blood transfusion (p < 0.001). In the logit model analysis, the main risk factor for HCV infection in the entire sample was blood transfusion (OR = 20.8, 95% CI: 5.7-75.7, p < 0.001). The association between HCV transmission and risk behavior among patients that contribute its spread in society such as dental healthcare (DHC) (OR = 0.98, 95% CI: 0.925-1.615, p < 0.05) and tattoos (OR = 0.75, 95% CI: 0.503-1.119). A non-significant increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, while, non-significant decrease in albumin in HCV-positive hemodialysis patients compared with HCV-negative dialysis patients. Our findings indicate a high incidence of HCV virus infection in patients who received blood. However, no transmitting risk appeared from such patients when using dental tools or tattoos tools.
Cite this article:
Zyad Hussein J. AL-Qaisi, Alaa Hussein J. AL-Qaisi, Wessal M. Khamis, Zaman Ahmed Hussein, Iman Rajab Mohammed. The transmission risk factors of hepatitis B and C infection in dental treating and tattooing among hemodialysis patients. Research Journal of Pharmacy and Technology 2023; 16(1):418-2. doi: 10.52711/0974-360X.2023.00071
Cite(Electronic):
Zyad Hussein J. AL-Qaisi, Alaa Hussein J. AL-Qaisi, Wessal M. Khamis, Zaman Ahmed Hussein, Iman Rajab Mohammed. The transmission risk factors of hepatitis B and C infection in dental treating and tattooing among hemodialysis patients. Research Journal of Pharmacy and Technology 2023; 16(1):418-2. doi: 10.52711/0974-360X.2023.00071 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-1-71
REFERENCES:
1. ShepardC. W., Finelli L. and Alter M. J., Global epidemiology of hepatitis C virus infection.Lancet Infectious Diseases.2005;5(9):558-67.
2. Engla N. E. W. and Journal N. D., New england journal.2018: 1169–1171.
3. Pozzetto B., Memmi M.,Garraud O., Roblin X. and Berthelot P., Health care-associated hepatitis C virus infection.World J. Gastroenterol.2014;20(46):17265-78.
4. Wood E. M.,Ang A. L. , Bisht A., Bolton‐Maggs P. H., Bokhorst A. G., Flesland O., Land K., Wiersum‐Osselton J. C., Schipperus M. R., Tiberghien P. and Whitaker B. I. , ,International haemovigilance: what have we learned and what do we need to do next?.Transfusion Medicine.2019;29(4): 221-230.
5. Webster D. P., Klenerman P. and Dusheiko G. M., Hepatitis C.Lancet.2015; 385(9973), 1124-1135.
6. Pham Y. H. and Rosenthal P., Chronic Hepatitis C Infection in Children.Adv. Pediatr.2016; 63(1):173–194.
7. Gravitz L.,Introduction: A smouldering public-health crisis.Nature.2011; 474(7350):S2-S4.
8. Fried M. W., Shiffman M. L , Reddy K R., Smith C., Marinos G.,Jr F. L. G. ,Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J.and Yu J., Peginterferon alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection.N Engl J Med.2002; 347(13), 975–982.
9. Bichoupan K., Tandon N., Crismale J. F., Hartman J., Del Bello D., Patel N., Chekuri S., Harty A., Ng M., Sigel K. M., Bansal M. B., Grewal P., Chang Ch. Y., Leong J., Im G. Y., Liu L. U., Odin J. A., Bach N., Friedman S. L., Schiano Th. D., Perumalswami P. V., Dieterich D. T. and Branch A. D., Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results. World Journal ofVirology.2017;6(4), 59–72.
10. J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. F. Hutin, and B. P. Bell, “The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide,” J. Hepatol.2006.
11. Miao Z., Xie Z., Miao J., Ran J., Feng Y. and Xia X.,Regulated Entry of Hepatitis C Virus into Hepatocytes. Viruses.2017;9(5),100.
12. H. S. Te, Epidemiology of Hepatitis B and C Viruses : A Global Overview.Clin. Liver Dis.2010;14(1):1–21.
13. Ringehan M., Mckeating J. A. and Protzer U., Viral hepatitis and liver cancer. Philosophical Transactions of The Royal Society B Biological Sciences.2017;372(1732):1-11.
14. Okoro R. N. and Farate V. T., The use of nephrotoxic drugs in patients with chronic kidney disease.Int. J. Clin. Pharm.2019;41(3):767-775.
15. Damiati S.,A pilot study to assess kidney functions and toxic dimethyl-arginines as risk biomarkers in women with low Vitamin D levels.J. Med. Biochem.2019; 38(2):145–152.
16. Rodríguez-Cubillo B., Carnero-Alcázar M. , Cobiella-Carnicer J. , Rodríguez-Moreno A. , Alswies A., Velo-Plaza M., Pérez-Camargo D. , Fructuoso A. S. and Castellanos L. M.., Impact of postoperative acute kidney failure in long-term survival after heart valve surgery. Interact. Cardiovasc. Thorac. Surg. 2019;29(1):35-42.
17. Azmi A. N., Tan S. S. and Mohamed R.,Hepatitis C and kidney disease: An overview and approach to management.World J. Hepatol.2015;7(1): 78–92.
18. Fabrizi F., Messa P., and Martin P., The Unravelled Link between Chronic Kidney Disease and Hepatitis C Infection.New J. Sci.2014; 2014: 1–9.
19. I. Corp, “IBM SPSS Statistics for WindowS,” VA, NY IBM Corp. 2010.
20. CDC, “CDC 2019 CKD fact sheet,” Cdc.2019; 1:1–6.
21. C. E. E. Ns, “Hepatitis C virus infection in dialysis and renal transplantation. 1997;51:981–999.
22. Yousif H., Sinjari A. and Bakr K. A.,Prevalence and Risk Factors of Hepatitis B and C Virus Infections Among Patients Undergoing Hemodialysis in Kurdistan , Iraq. 2018;18(5).
23. Khattab O. S.,Renal Data from Arab World.2008;19(1):110–115.
24. Pereira B. J. G. and Levey A. S., Hepatitis C virus infection in dialysis and renal transplantation.Kidney Int.1997;51(4): 981–999.
25. Alvarez K. J., Befus M., Herzig C. T. A. and Larson E.,Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities.J. Infect. Public Health.2014;7(6): 517–521.
26. Edris A., Nour M. O., Zedan O. O., Mansour A. E.,Ghandour A. A., and T.Omran, Seroprevalence and risk factors for hepatitis B and C virus infection in Damietta Governorate, Egypt.East. Mediterr. Heal. J.2014; 20(10): 605–613.
27. Olayinka A., Seroprevalence of Hepatitis B infection in Nigeria: A national survey.Am. J. Trop. Med. Hyg.2016;95(4): 902–907.
28. L. I. Ainley and P. E. Hewitt, Haematology patients and the risk of transfusion transmitted infection.2018;(Jan):473–483.
29. Jakupi X., Mlakar J., Lunar M. M. , Seme K. , Rudhani I. , Raka L., Vince A. and Poljak M., A very high prevalence of hepatitis C virus infection among patients undergoing hemodialysis in Kosovo : a nationwide study.BMC Nephrol.2018;19(3).
30. Chan T. M., Lok A. S. F. and Cheng I. K. P., Hepatitis C infection among dialysis patients: A comparison between patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis.Nephrol. Dial. Transplant.1991; 6(12):944–947.
31. Alfurayh O., Sobh M., Buali AbdulRahman , Ali M. A., Barri Y., Qunibi W., Taher S., Hepatitis C virus infection in chronic haemodialysis patients, a clinicopathologic study. Nephrology Dialysis Transplantation, 7(4),327–332 (1992)
32. Dong Y. , Qiu Ch. , Xia X. , Wang J. , Zhang H. , Zhang X. and Xu J. ,Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study.Arch. Virol.2015;, 160(4):929–936.
33. D. Prati,Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review.J. Hepatol.2006;45(4): 607–616.
34. Alter M. J., Seeff L. B., Bacon B. R., Thomas D. L., Rigsby M. O., and Di Bisceglie A. M.,Testing for hepatitis C virus infection should be routine for persons at increased risk for infection.Ann. Intern. Med.2004;141(9):715–717.
35. Ghany M. G., Strader D. B., Thomas D. L., and Seeff L. B., Diagnosis, management, and treatment of hepatitis C: An update.Hepatology.2009; 49(4):1335–1374.
36. Alsamarai A. M., Abdulrazaq G. and Alobaidi A. H., Seroprevalence of Hepatitis C Virus in Iraqi Population Seroprevalence of Hepatitis C Virus in Iraqi Population.2016;1(3):1-9.
37. Klevens R. M. and Moorman A. C., Hepatitis C virus An overview for dental health care providers,” J. Am. Dent. Assoc.2013;144(12):1340–1347.
38. Alharbi G., Shono N., Alballaa L. and Aloufi A., Knowledge , attitude and compliance of infection control guidelines among dental faculty members and students in KSU.BMC Oral Health .2019;19(1):1–8.
39. Jafari S., Copes R., Baharlou S., Etminan M. and Buxton J., Tattooing and the risk of transmission of hepatitis C: A systematic review and meta-analysis.International Journal of Infectious Diseases.2010;14(11): e928-e940.
40. Laumann A. E. and Derick A. J., Tattoos and body piercings in the United States: A national data set.J. Am. Acad. Dermatol.2006;55(3):413-421.
41. Breuner C. C.,Levine D. A. and The Committee On Adolescence, Adolescent and young adult tattooing, piercing, and scarification.The American Academy of Pediatrics.2017; 140(4):1-16.
42. Petrochko J. M , Krakowski A. C. , Donnelly C. , Wilson J. B. , Irick J. B. , Stawicki S. P. , Tattoo-associated complications and related topics: A comprehensive review.Int. J. Acad. Med.2019; 5(1):19–50.
43. Jafari S., Copes R.,Baharlou S., Etminan M. and Buxton J.,Tattooing and the risk of transmission of hepatitis C: A systematic review and meta-analysis.Int. J. Infect. Dis.2010;14(11): e928–e940.
44. Uto H., Mawatari S., Kumagai K., Ido A., and Tsubouchi H.,Clinical features of Hepatitis C virus carriers with persistently normal alanine aminotransferase levels.Hepat. Mon.2012;12(2):77–84.
45. Mathurin P., Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.Hepatology.1998; 27(3):868–872.
46. Shakil A. O. , Conry-Cantilena C. , Alter H. J. , Hayashi P. , Kleiner D. E. , Tedeschi V. , Krawczynski K. , Conjeevaram H. S., Sallie R. , Di Bisceglie A. M. , Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features.Ann. Intern. Med.1995;123(5):330–337.